Edesa Biotech filings document the formal disclosure record of a clinical-stage biotechnology issuer focused on host-directed therapeutics for immuno-inflammatory diseases. Recent Form 8-K reports cover clinical-study disclosures for paridiprubart in Acute Respiratory Distress Syndrome, operating and financial results, material-event updates and agreements connected to funded development work.
The company’s filings also address capital-structure matters, including common-share sales under at-the-market offering arrangements and related Form S-3 prospectus supplements. Proxy materials cover shareholder voting matters, board governance, executive compensation and equity-award disclosures for the public company.
Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan acquired 18,677 restricted share units on November 4, 2026; the units vested in full upon grant under the issuer’s 2019 Equity Incentive Compensation Plan. His directly held Common Shares totaled 952,272 after the grant. The report also lists indirect Common Share positions through three companies and The New Nijhawan Family Trust 2015.
Edesa Biotech, Inc. (EDSA) is the issuer in an amended ownership report listing shared voting and dispositive power over 1,172,617 common shares for Integrated Core Strategies (US) LLC and 1,178,577 shares each for Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. Each cover page reports 8.7% of the class as of September 30, 2026.
The report says securities potentially attributed to Millennium Management, Millennium Group Management and Israel A. Englander are held by entities subject to voting control and investment discretion of Millennium Management and/or managers that may be controlled by Millennium Group Management and Englander. It states that this disclosure alone is not an admission of beneficial ownership by those three filers.
Edesa Biotech, Inc. (EDSA) Chief Executive Officer Pardeep Nijhawan acquired 27,602 shares through restricted share units on October 28, 2026; the units vested in full upon grant under the 2019 Equity Incentive Compensation Plan. The award was received in lieu of 90% of monthly base salary otherwise payable in cash, following an annual base salary increase from $357,696 to $657,423, retroactive from July 1 through October 10, 2026. Nijhawan’s direct holdings after the grant were 933,595 shares.
On October 23, 2026, the Board of Edesa Biotech, Inc. (EDSA) approved annual base-salary increases for Chief Executive Officer Dr. Pardeep Nijhawan, from $357,696 to $657,423; President Dr. Michael Brooks, from $335,340 to $591,681; and Chief Financial Officer Peter Weiler, from $300,000 to $525,938. The increases are retroactive to July 1, 2026.
For Dr. Nijhawan, 90% of monthly base salary otherwise payable in cash will continue to be issued as fully vested restricted share units under the company's 2019 Equity Incentive Compensation Plan. The executive officers' base salaries had last been adjusted in 2023 before these increases.
Edesa Biotech, Inc. (EDSA) said the FDA cleared the Investigational New Drug application for EB06, allowing its Phase 2 clinical study in vitiligo to expand recruitment to the United States. Recruitment is underway in Canada; first U.S. sites are expected to begin enrolling subjects next quarter, and topline data are anticipated in fourth quarter 2027.
The double-blind, placebo-controlled study will evaluate EB06, a fully human monoclonal antibody targeting CXCL10, in up to 80 adults with moderate-to-severe nonsegmental vitiligo. Participants are randomized 1:1 to EB06 or placebo every two weeks through Week 22. Safety and efficacy remain subject to clinical evaluation.
Edesa Biotech, Inc. CEO, director and 10% owner Pardeep Nijhawan acquired 6,893 common shares on October 5, 2026, through restricted share units that vested in full upon grant under Edesa’s 2019 Equity Incentive Compensation Plan. His reported direct holdings after the award were 905,993 shares.
Edesa Biotech, Inc. (symbol: EDSA) is the issuer of record for a Form 4 filing submitted to the SEC.
Edesa Biotech, Inc. (EDSA) has a new large shareholder group reported on Schedule 13G. Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico jointly report beneficial ownership of 953,739 Edesa common shares, representing 6.9% of the class.
The position consists of 703,739 common shares plus warrants to acquire an additional 250,000 common shares, subject to a 9.99% beneficial ownership limitation. The percentage is based on 13,503,723 common shares outstanding immediately after an offering, as reported in a prospectus dated August 20, 2026. Voting and dispositive power over the 953,739 shares is shared among the Stonepine entities and Plexico, and the Partnership holds the stock for the benefit of its investors.
Edesa Biotech, Inc. (EDSA) received an amended Schedule 13D (Amendment No. 11) from Dr. Pardeep Nijhawan and related entities updating their beneficial ownership in the company’s common shares.
Dr. Nijhawan is reported as the beneficial owner of 2,613,492 common shares, representing approximately 16.31% of Edesa’s outstanding common shares, including shares held directly, through options, restricted share units, warrants, and preferred shares, as well as through several Ontario entities and a family trust. The filing is based on 14,193,356 common shares outstanding as of August 25, 2026, plus specified derivative securities deemed outstanding for this holder. The amendment also notes that since the prior amendment, Dr. Nijhawan received 3,378 restricted share units on July 2, 2026 and 5,324 restricted share units on August 3, 2026, each vesting in full upon grant and issued in lieu of partial salary.
Edesa Biotech, Inc. (EDSA) is the subject of an amended Schedule 13D/A filed by Velan Capital–affiliated entities following an underwritten public offering on August 21, 2026. The Velan Master, Horizon and Opportunity II funds acquired additional common shares and warrants in the transaction.
Velan Master purchased 445,100 Shares and 445,100 New Warrants for $2,448,050, and Velan Horizon purchased 9,445 Shares and 9,445 New Warrants for $51,948. Overall, Velan Capital and related reporting persons may be deemed to beneficially own 1,356,455 Shares, or 9.99% of the class, based on 13,503,723 Shares outstanding plus certain convertible Preferred Shares, subject to ownership caps. The New Warrants are exercisable into an equal number of Shares at $7.50 per Share, until the earlier of 18 months from issuance or 30 days after Edesa publicly announces Phase 2 vitiligo topline data for EB06, and are subject to a 9.99% Warrant Ownership Limitation. Without the Ownership Limitation and Warrant Ownership Limitation, the group states it would collectively beneficially own 4,694,923 Shares, or 27.8% of the outstanding Shares.